Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other financing activities (2021 - 2025)

Historic Other financing activities for Akebia Therapeutics (AKBA) over the last 4 years, with Q1 2025 value amounting to $63000.0.

  • Akebia Therapeutics' Other financing activities fell 9160.0% to $63000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $63000.0, marking a year-over-year decrease of 9504.72%. This contributed to the annual value of $1.3 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Akebia Therapeutics reported Other financing activities of $63000.0 as of Q1 2025, which was down 9160.0% from $522000.0 recorded in Q3 2024.
  • Over the past 5 years, Akebia Therapeutics' Other financing activities peaked at $44.8 million during Q1 2021, and registered a low of $63000.0 during Q1 2025.
  • Over the past 4 years, Akebia Therapeutics' median Other financing activities value was $750000.0 (recorded in 2024), while the average stood at $17.2 million.
  • In the last 5 years, Akebia Therapeutics' Other financing activities tumbled by 1068.04% in 2022 and then tumbled by 9160.0% in 2025.
  • Over the past 4 years, Akebia Therapeutics' Other financing activities (Quarter) stood at $44.8 million in 2021, then dropped by 10.68% to $40.0 million in 2022, then tumbled by 98.7% to $522000.0 in 2024, then tumbled by 87.93% to $63000.0 in 2025.
  • Its last three reported values are $63000.0 in Q1 2025, $522000.0 for Q3 2024, and $750000.0 during Q1 2024.